Dr. Charles Scott Buess, MD

Dr. Buess practices at Katmai Oncology Group in Anchorage, Alaska.

Dr. Buess' NPI, 1124548284, was assigned on June 20, 2017. Dr. Buess holds Alaska license 216923.

Dr. Buess' primary practice is Katmai Oncology Group, at 3851 Piper St, Anchorage, AK 99508 in Anchorage Borough. The practice phone is (907) 562-0321.

Dr. Buess' primary practice is Katmai Oncology Group in Anchorage, Alaska. Dr. Buess is also affiliated with Providence Alaska Medical Center. The medical group on file is Katmai Oncology Group. Dmand AI also links Dr. Buess to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Buess practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Buess' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Buess' licenses on file in 2 states: Alaska and Texas.

CMS data shows 4,461 Medicare services from Dr. Buess across 18 procedure codes in 2024, for 207 Medicare patients. Medicare paid $73,814 for them. Every service was in an office.

CMS counts 207 Medicare patients who saw Dr. Buess in 2024. The largest group is 65 to 74, with 122 patients. 69% of them have high blood pressure, and 58% have high cholesterol. 16% are also on Medicaid. Their average risk score is 1.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Buess' median patient age at 65, with 55% women.

In 2024, Dr. Buess wrote 62 Medicare Part D claims for 16 patients. 85% of them were for generic drugs. CMS names the drug for 26 of them, across 1 drug with 11 or more claims each, at $298 in total drug cost. In 2021, CMS named 41 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Buess for performance year 2024, reported as part of a group. Dr. Buess accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Buess as offering telehealth.

Dmand AI links 4 papers to Dr. Buess, published from 2019 to 2020. 2020 was the busiest year, with 3. Dr. Buess has published most often in Cureus. Dr. Buess' most frequent co-authors are Yasmine Hussein Agha, MD, Corey Braet and Jeremy M. Deutsch, MD.

CMS Open Payments shows 62 general payments to Dr. Buess from 28 drug and device companies from 2021 to 2025. Speaker and faculty fees make up the largest share, 61% of the total. BeiGene, Ltd. paid the most, $2,750.